A Phase 3 interventional study of Bictegravir/Lenacapavir (BIC/LEN) FDC and Lenacapavir in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 104 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH) who are successfully treated with B/F/TAF (virologically suppressed).
The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) FDC tablets versus continuing on B/F/TAF (50/200/25 mg) FDC tablets in virologically suppressed PWH.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Chronic virus (HBV) infection, as determined by either:
Any of the following laboratory values at screening:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed-dose combination (FDC) tablets to bictegravir/lenacapavir (BIC/LEN) 75/50 mg FDC tablets + placebo-to-match (PTM) B/F/TAF tablets, administered orally, once daily up to 48 weeks. Participants will also receive a 2-day oral pharmacokinetic (PK) loading dose of LEN 600 mg on Days 1 and 2, in addition to the daily doses of BIC/LEN 75/50 mg and PTM B/F/TAF tablets starting on Day 1. At the end of blinded treatment (EBT) participants will enter the open label (OL) phase and continue to receive BIC/LEN 75 mg/50 mg FDC tablets through at least 48 weeks in the OL phase. At the OL Week 48, participants will be given an option to continue to receive BIC/LEN FDC tablets.
Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC · Drug: Lenacapavir · Drug: Placebo to match B/F/TAF
Participants will continue with their B/F/TAF 50/200/25 mg tablets and start PTM BIC/LEN tablets on Day 1 administered orally, once daily up to 48 weeks. Participants will receive PTM oral LEN PK loading tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2). Participants who complete the EBT will be given an option to enter the OL phase to receive BIC/LEN FDC tablets.
Drug: B/F/TAF · Drug: Placebo to match BIC/LEN FDC · Drug: Placebo to match Lenacapavir
Participants from Treatment Group 1 will receive BIC/LEN FDC tablets through at least OL Week 48. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets. Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets. Participants from Treatment Group 2 who enter the OL phase will also receive a 2-day oral loading dose of LEN 600 mg (2 × 300 mg LEN on Day 1 and on Day 2). All participants who enter the OL phase may continue to receive BIC/LEN FDC tablets daily until study drug is available or until Gilead Sciences (Gilead) elects to discontinue the study.
Drug: Bictegravir/Lenacapavir (BIC/LEN) FDC · Drug: Lenacapavir
Drug pages: Bictegravir · Lenacapavir
Tablets administered orally without regard to food
Also known as: Bixlenvo™
Tablets administered orally without regard to food
Also known as: GS-6207
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
Tablets administered orally without regard to food
Also known as: Biktarvy ®
Tablets administered orally without regard to food
Tablets administered orally without regard to food
Tablets administered orally without regard to food
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and participants who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window was between Days 295 and 378 (inclusively). Percentages were rounded off.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.
Time frame: Week 48
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48
Time frame: Baseline, Week 48
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC/LEN FDC, Treatment Group 1) or 30 days (for B/F/TAF, Treatment Group 2) or any AE leading to study drug discontinuation. Percentages were rounded off.
Time frame: First dose date up to Week 48
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-Defined Snapshot Algorithm
Time frame: Week 96
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by US FDA-Defined Snapshot Algorithm
Time frame: Week 96
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 96
Time frame: Week 96
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 96
Time frame: First dose date up to Week 96
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot Algorithm
Time frame: Week 144
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot Algorithm
Time frame: Week 144
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 144
Time frame: Week 144
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144
Time frame: First dose date up to Week 144
Participants were enrolled at study sites in Asia, Europe, North America, Oceania and South America.
| Milestone | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| Started | 384 | 193 |
| Completed | 0 | 0 |
| Not completed | 384 | 193 |
| Withdrew: Still on study | 359 | 173 |
| Withdrew: Withdrew consent | 13 | 9 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Investigator's discretion | 1 | 2 |
| Withdrew: Randomized but never treated | 1 | 2 |
| Withdrew: Death | 0 | 1 |
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and participants who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window was between Days 295 and 378 (inclusively). Percentages were rounded off.
| percentage of participants | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm | 1.3 | 1.0 |
Participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.
| percentage of participants | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm | 93.5 | 90.6 |
| cells/µL | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| Baseline | 755 ± 301.4 | 714 ± 271.8 |
| Change at Week 48 | -20 ± 192.5 | -6 ± 164.0 |
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC/LEN FDC, Treatment Group 1) or 30 days (for B/F/TAF, Treatment Group 2) or any AE leading to study drug discontinuation. Percentages were rounded off.
| percentage of participants | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48 | 72.8 | 72.3 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over All-Cause Mortality and Adverse Events: Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | 0/384 (0%) | 27/383 (7%) | 101/383 (26.4%) |
| Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | 1/193 (0.5%) | 13/191 (6.8%) | 46/191 (24.1%) |
| Event | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/383 | 2/191 |
| Coronary artery diseaseCardiac disorders | 0/383 | 1/191 |
| Abdominal painGastrointestinal disorders | 0/383 | 1/191 |
| Gait disturbanceGeneral disorders | 0/383 | 1/191 |
| CholecystitisHepatobiliary disorders | 0/383 | 1/191 |
| Escherichia bacteraemiaInfections and infestations | 0/383 | 1/191 |
| Gastroenteritis bacterialInfections and infestations | 0/383 | 1/191 |
| Postoperative abscessInfections and infestations | 0/383 | 1/191 |
| SepsisInfections and infestations | 0/383 | 1/191 |
| Staphylococcal infectionInfections and infestations | 0/383 | 1/191 |
| Event | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/383 | 9/191 |
| NasopharyngitisInfections and infestations | 30/383 | 13/191 |
| Upper respiratory tract infectionInfections and infestations | 29/383 | 9/191 |
| NauseaGastrointestinal disorders | 20/383 | 11/191 |
| HeadacheNervous system disorders | 22/383 | 6/191 |
| Covid-19Infections and infestations | 5/383 | 10/191 |
The Safety Analysis Set included all participants who were randomized and took at least 1 dose of study drug.
| Age, Categorical(Participants) | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 339 | 168 | 507 |
| >=65 years | 44 | 23 | 67 |
| Age, Continuous(Years) | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | Total |
|---|---|---|---|
| Mean | 48 ± 12.7 | 50 ± 11.9 | 49 ± 12.5 |
| Sex: Female, Male(Participants) | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | Total |
|---|---|---|---|
| Female | 69 | 42 | 111 |
| Male | 314 | 149 | 463 |
| Race/Ethnicity, Customized(Participants) | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | Total |
|---|---|---|---|
| Race — White | 199 | 111 | 310 |
| Race — Black or African American | 113 | 44 | 157 |
| Race — Asian | 51 | 26 | 77 |
| Race — Other or More Than One Race | 18 | 9 | 27 |
| Race — American Indian or Alaska Native | 1 | 1 | 2 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | Total |
|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 277 | 141 | 418 |
| Ethnicity — Hispanic or Latino | 106 | 49 | 155 |
| Ethnicity — Not Collected | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg | Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg | Total |
|---|---|---|---|
| United States | 243 | 114 | 357 |
| Taiwan | 31 | 15 | 46 |
| Canada | 17 | 14 | 31 |
| Germany | 21 | 7 | 28 |
| Japan | 15 | 7 | 22 |
| Australia | 11 | 9 | 20 |
| Italy | 12 | 6 | 18 |
| Spain | 4 | 8 | 12 |
| United Kingdom | 9 | 2 | 11 |
| Argentina | 5 | 4 | 9 |
| Mexico | 6 | 2 | 8 |
| Puerto Rico | 6 | 1 | 7 |
| South Korea | 3 | 2 | 5 |
Showing the first 100 of 104 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2024 to primary completion in Oct 2025, 19 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Lenacapavir